Clinical data | |
---|---|
Trade names | Flumarin |
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C15H18F2N6O7S2 |
Molar mass | 496.46 g·mol |
3D model (JSmol) | |
Melting point | 82.5 to 87.5 °C (180.5 to 189.5 °F) |
SMILES
| |
InChI
| |
(what is this?) (verify) |
Flomoxef is an oxacephem antibiotic that was developed by Shionogi.
It has been classified either as a second-generation or fourth-generation cephalosporin.
It was patented in 1982 and approved for medical use in 1988 under the trade name Flumarin.
References
- Masuda Z, Kurosaki Y, Ishino K, Yamauchi K, Sano S (April 2008). "Pharmacokinetic analysis of flomoxef in children undergoing cardiopulmonary bypass and modified ultrafiltration". General Thoracic and Cardiovascular Surgery. 56 (4): 163–169. doi:10.1007/s11748-007-0208-5. PMID 18401677. S2CID 23845740.
- Ito M, Ishigami T (1991). "The meaning of the development of flomoxef and clinical experience in Japan". Infection. 19 (Suppl 5): S253–S257. doi:10.1007/bf01645536. PMID 1783441. S2CID 25339977.
- Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 496. ISBN 9783527607495.
This systemic antibiotic-related article is a stub. You can help Misplaced Pages by expanding it. |